N. Patel

TL;DR: More severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE.

TL;DR: While COVID-19 vaccination prevents severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness and further risk mitigation strategies are likely needed to protect this selected high-risk population.

TL;DR: In this article , the authors examined baseline predictors of prolonged COVID-19 symptom duration (defined as lasting ≥28 days) using logistic regression and found that patients experiencing prolonged symptom duration had higher RAPID3 scores (p=0.007) and more pain (p<0.03) compared to those without prolonged symptoms.

TL;DR: The Glucocorticoid Toxicity Index (GTI) as mentioned in this paper was developed by an international group of subspecialty physician experts as a clinician-facing clinical trials outcome measure, is a standardized, validated measure of the phenomenon known as GC toxicity.

TL;DR: The proportion of patients with SARD with severe COVID-19 has diminished since early in the pandemic, particularly during the most recent time periods, including the initial Omicron wave.